
|Videos|November 1, 2013
The Challenges of Using Ki67 as a Tool in Breast Cancer
Author(s)Torsten O. Nielsen, MD, PhD, FRCPC
Torsten O. Nielsen, MD, PhD, FRCPC, a professor of pathology at the University of British Columbia, discusses the difficulties when using Ki67 to measure proliferation in breast cancer.
Advertisement
Clinical Pearls
Torsten O. Nielsen, MD, PhD, FRCPC, a professor of pathology at the University of British Columbia, discusses the difficulties when using Ki67 to measure proliferation in breast cancer.
- Ki67 index values are difficult to reproduce between pathologists
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
3
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
4
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
5







































